New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
Themis will market this drug with the brand name REMITHEM.
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
The Ministry of Ayush endeavour is to get entry level NABH certification for 12,500 Ayush Wellness Centers by the end of 2023
To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
_256_384.jpg)
Through this important initiative, Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in the Aptivate Champion Run
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
Subscribe To Our Newsletter & Stay Updated
